Condition

Rheumatoid Arthritis (RA)

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 177 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials177

Recruiting62

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

FT839 in Autoimmune DiseasesNCT07800871 · 2026-10-01

The Effect of Nicorandil on Rheumatoid Arthritis PatientsNCT07730723 · 2026-09-06

Twenty-four Hour Movement Behaviors and Atherosclerotic RiskNCT07774507 · 2026-09-01

Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid ArthritisNCT07745426 · 2026-08-01

A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid ArthritisNCT07684157 · 2026-07-23

Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF InhibitorsNCT07802678 · 2026-07-14

A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)NCT07564154 · 2026-07-13

Study of S-4321 in Participants With an Autoimmune or Immune-mediated DiseaseNCT07455578 · 2026-06-01

BloodTrackR Usability and Concordance Study (BUCS): Evaluating a Smart Home-Based Blood Collection Platform for Remote Monitoring in Rheumatoid ArthritisNCT07660029 · 2026-06-01

Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)NCT07627893 · 2026-06-01

Desloratadine as Adjunct Therapy for Rheumatoid ArthritisNCT07632872 · 2026-05-23

Effect of Roflumilast as Add-On Therapy in Rheumatoid ArthritisNCT07632846 · 2026-05-19

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid ArthritisNCT06933134 · 2026-04-23

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)NCT07611747 · 2026-04-22

Controlling Hyperactive Immunity With Long-lived LymphocytesNCT07473154 · 2026-04-10

An Investigation of the Effect of Smartphone Usage Levels on Cervical Posture, Tongue Pressure, Balance, and Neck Disability in Individuals With Rheumatoid Arthritis and Ankylosing SpondylitisNCT07627542 · 2026-04-09

Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis FlaresNCT07245732 · 2026-04-01

Effect of Lavender Aromatherapy Massage on Pain and Wrist Mobility in Rheumatoid ArthritisNCT07456657 · 2026-04-01

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesNCT07087912 · 2026-03-16

Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With SulfasalazineNCT07416656 · 2026-03-10

A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).NCT07234773 · 2026-03-06

A Study of F8IL10 Intra-articular Treatment in Rheumatoid ArthritisNCT07245992 · 2026-03-04

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid ArthritisNCT07524244 · 2026-02-17

Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCTNCT07438652 · 2026-01-17

Clinical Study of (A-319) in the Treatment of Active Rheumatoid ArthritisNCT07347860 · 2026-01-08

Plant-Based Diet for Patients With Rheumatoid ArthritisNCT07268326 · 2025-12-15

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisNCT07258849 · 2025-12-02

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101NCT07403188 · 2025-11-24

Integrated Clinical Study of Traditional Chinese and Western Medicine for Refractory Rheumatoid ArthritisNCT07721142 · 2025-10-15

A Phase 1 Study of ADI-001 in Rheumatoid ArthritisNCT07100873 · 2025-10-10

National Cohort of Subjects at Risk of Developing Rheumatoid ArthritisNCT06876064 · 2025-10-07

Oxidative Stress in Autoimmune Rheumatic DiseasesNCT07536529 · 2025-10-06

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic DiseasesNCT07160231 · 2025-09-15

Anticholinergic Burden and Osteoporosis in Rheumatoid ArthritisNCT06812481 · 2025-09-15

Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid ArthritisNCT07408024 · 2025-09-10

Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological TherapyNCT07678112 · 2025-08-28

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid ArthritisNCT07484243 · 2025-08-22

Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health ParticipantsNCT07182656 · 2025-08-18

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) TherapeuticNCT07123038 · 2025-07-22

Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid ArthritisNCT06906549 · 2025-07-11

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid ArthritisNCT06946199 · 2025-06-23

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human ArthritisNCT07013110 · 2025-06-18

The Clinical Study on the Treatment of Refractory RA With UTAA91 InjectionNCT07001956 · 2025-05-30

A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesNCT06978647 · 2025-05-19

Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid ArthritisNCT07138729 · 2025-05-10

HiSCs in the Treatment of Rheumatoid ArthritisNCT06947746 · 2025-05-01

Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study)NCT06913907 · 2025-04-10

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and EfficacyNCT07150000 · 2025-04-01

A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis PatientsNCT06946641 · 2025-03-31

Dose Response of Exercise for Arthritis ManagementNCT06880653 · 2025-03-28

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic DiseasesNCT06647069 · 2025-03-27

Treatment With Auricular Vagus Nerve Stimulation in Rheumatoid Arthritis - the TRAVAGA StudyNCT06779123 · 2025-03-21

Could a Feedback Device Help Manage Work-related Shoulder Disorders?NCT06693479 · 2025-03-01

L-carnitine Supplementation in Rheumatoid Arthritis PatientsNCT06753565 · 2024-12-31

Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic ArthritisNCT06628206 · 2024-12-15

COVID-19 Booster and IIV Schedule in Immunocompromised HostsNCT06599658 · 2024-11-20

AYLo - AutoimmunitY and Loss of yNCT06696027 · 2024-11-15

Safety Study of CC312 in Autoimmune Disease PatientsNCT06888960 · 2024-11-08

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid ArthritisNCT06671054 · 2024-10-01

A RWS of SC MTX in Chinese RA PatientsNCT07463937 · 2024-09-03

Common interventions

Leading sponsors

AbbVie 14 Assiut University 5 Bristol-Myers Squibb 4 Sohag University 4 Peking University People's Hospital 3 Tanta University 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 3 Ain Shams University 2 Antares Pharma Inc. 2 Astellas Pharma Inc 2 Horus University 2 Jiangsu Simcere Pharmaceutical Co., Ltd. 2 Kali Therapeutics, Inc. 2 Sint Maartenskliniek 2 University of Bonn 2

Trial status mix

RECRUITING62

COMPLETED53

NOT_YET_RECRUITING33

TERMINATED10

ACTIVE_NOT_RECRUITING7

UNKNOWN5

ENROLLING_BY_INVITATION4

SUSPENDED2

WITHDRAWN1

Phase mix

NA38

PHASE229

PHASE127

PHASE417

PHASE314

EARLY_PHASE15

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.